Stelara still effective years later in CD in UC

The long-term efficacy of the Janssen drug Stelara (ustekinumab) has been demonstrated in two common inflammatory conditions.

Janssen, part of Johnson & Johnson (NYSE: JNJ), has announced final pooled long-term safety results for the drug through five years in moderately to severely active Crohn’s disease and four years in moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension study in moderately to severely active UC.

Data support the longstanding safety profile of Stelara, the first biologic treatment to selectively inhibit the interleukin (IL)-12 and IL-23 pathways, across all inflammatory bowel disease (IBD) approved indications.